arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Roivant Sciences Ltd.

ROIV

$36.63 ▼ -1.59 (-4.16%) at close

6 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Neutral

auto_awesome

Analytical Summary

Roivant Sciences Ltd. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $25.4B

Dividend Yield —

Revenue Growth -71.6% ↗

Op. Margin —

ROIC -17.1% ↗

FCF / Share $-1.09 ↗

Trailing P/E —

Price / Book 5.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$8.26M

↓ -71.6% —

Net Income Profit after all expenses

$-299.77M

↓ -74.3% —

FCF / Share Free cash flow per share

$-1.09

↑ +6.0% —

Long-Term Debt Long-term obligations

$430.59M

↑ +14.7% —

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Mar 31, 2026 10-K ↗	FY 2024 Mar 31, 2025 10-K ↗	FY 2023 Mar 31, 2024 10-K ↗	FY 2022 Mar 31, 2023 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Mar 31, 2021 10-K ↗
Revenue Growth YoY (%)	-71.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-995%)	-76.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1059%)	103.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1196%)	10.8% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+36%)	132.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1554%)	—
EPS Growth YoY (%)	-79.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	-12.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-74.3% Weak Weak Year-over-year change in net income	N/M	N/M	-19.4% Weak Weak Year-over-year change in net income	-4.5% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	6.0% Fair ↑ Fair Improving Year-over-year change in free cash flow	-18.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	18.5% Good Good Year-over-year change in free cash flow	-15.7% Weak Weak Year-over-year change in free cash flow	—	—
Revenue CAGR 3Y (%)	-48.7% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-19.3% Weak Weak Compound annual revenue growth over 3 years	73.7% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—
Revenue CAGR 5Y (%)	-19.1% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Mar 31, 2026 10-K ↗	FY 2024 Mar 31, 2025 10-K ↗	FY 2023 Mar 31, 2024 10-K ↗	FY 2022 Mar 31, 2023 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Mar 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	-50.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-7.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.5% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%
FCF / Net Income (x)	2.53x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	4.91x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-0.18x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Mar 31, 2026 10-K ↗	FY 2024 Mar 31, 2025 10-K ↗	FY 2023 Mar 31, 2024 10-K ↗	FY 2022 Mar 31, 2023 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Mar 31, 2021 10-K ↗
Return on Invested Capital (%)	-17.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-22.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	65.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-77.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-72.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-54.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%
Return on Capital (%) (%)	-9.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-18.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	58.7% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	-49.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-52.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-41.4% Weak Weak Operating profit relative to total assets Optimal: > 10%
Return on Common Equity (%) (%)	-6.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	-3.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-124%)	72.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+386%)	-87.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-681%)	-51.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-440%)	-45.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-400%)

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Mar 31, 2026 10-K ↗	FY 2024 Mar 31, 2025 10-K ↗	FY 2023 Mar 31, 2024 10-K ↗	FY 2022 Mar 31, 2023 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Mar 31, 2021 10-K ↗
Debt to Equity (x)	—	—	0.07x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-88%)	0.32x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-46%)	0.13x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-79%)	0.09x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-84%)
Interest Coverage (x)	—	-168.25x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	121.97x Excellent ↑ Excellent Improving Operating income divided by interest expense Optimal: > 5x	-42.02x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-191.97x Weak Weak Operating income divided by interest expense Optimal: > 5x	-381.24x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$-1.42B	$-2.72B	$-6.11B	$-1.30B	$-1.85B	$-1.88B
Debt / EBITDA (x)	—	—	0.10x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.32x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.16x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.16x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x

📊 What does each share earn? 6 metrics

Metric	FY 2025 Mar 31, 2026 10-K ↗	FY 2024 Mar 31, 2025 10-K ↗	FY 2023 Mar 31, 2024 10-K ↗	FY 2022 Mar 31, 2023 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Mar 31, 2021 10-K ↗
Revenue per Share (USD)	$0.01	$0.04	$0.16	$0.09	$0.08	—
Basic EPS, GAAP (USD)	$-0.43	$-0.24	$5.55	$-1.42	$-1.26	—
Free Cash Flow per Share (USD)	$-1.09	$-1.16	$-0.98	$-1.20	$-1.04	—
Book Value per Share (USD)	$6.28	$6.74	$7.40	$1.52	$2.38	$2.76
Tangible Book Value per Share (USD)	$6.28	$6.74	$7.23	$1.33	$2.38	$2.76
Basic Weighted Avg Shares (shares)	693.86M	725.40M	783.25M	712.79M	669.75M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Mar 31, 2026 10-K ↗	FY 2024 Mar 31, 2025 10-K ↗	FY 2023 Mar 31, 2024 10-K ↗	FY 2022 Mar 31, 2023 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Mar 31, 2021 10-K ↗
Working Capital (USD)	$4.89B	$4.85B	$6.47B	$1.53B	$1.96B	$1.97B
LT Debt (USD)	—	—	$430.59M	$375.51M	$210.03M	$170.28M
Total Equity (USD)	$4.53B	$4.69B	$5.97B	$1.16B	$1.66B	$1.80B

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Mar 31, 2026 10-K ↗	FY 2024 Mar 31, 2025 10-K ↗	FY 2023 Mar 31, 2024 10-K ↗	FY 2022 Mar 31, 2023 10-K ↗	FY 2021 Mar 31, 2022 10-K ↗	FY 2020 Mar 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$8.26M	$29.05M	$124.80M	$61.28M	$55.29M	$23.80M
Depreciation Expense (USD)	$3.35M	$14.07M	$22.04M	$18.86M	$5.93M	—
Net Income, GAAP (USD)	$-299.77M	$-171.98M	$4.35B	$-1.01B	$-845.26M	$-809.23M
Operating Cash Flow (USD)	$-750.35M	$-839.45M	$-765.27M	$-843.39M	$-677.73M	$-552.14M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 25 quarters

Roivant Sciences Ltd.

Analytical Summary

6-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare ROIV with peers